DUKE UNIVERSITY - NICHD: R&D: BESPOKE GENE THERAPY CONSORTIUM (BGTC) - SUPPORT FOR NIH-SPONSORED CLINICAL TRIALS: NON-SEVERABLE

PIID: 75N94026F00002

Signed Date: Sep 24, 2026Effective Date: Sep 28, 2026End Date: Closes in 1435 days

Award $

$8.3M

Vendor

DUKE UNIVERSITY

NAICS

541715

Signed Date

Sep 24, 2026

Key Details

Dollars Obligated

$8.3M

Base & All Options

$8.3M

Awarding Agency

Awarding Sub-Agency

National Institutes of Health

NAICS Code

Parent IDIQ (PIID)

75N94025D00003

Product Service Code

AN11 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Place of Performance

DURHAM, NC

NICHD: R&D: BESPOKE GENE THERAPY CONSORTIUM (BGTC) - SUPPORT FOR NIH-SPONSORED CLINICAL TRIALS: NON-SEVERABLE

On Sep 24, 2026, Department of Health and Human Services obligated $8,301,883 to DUKE UNIVERSITY for nichd: r&d: bespoke gene therapy consortium (bgtc) - support for nih-sponsored clinical trials: non-severable. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). Competition extent: full and open competition. Performance is located in DURHAM, NC. The contract is scheduled through Sep 27, 2030. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.